GET IN TOUCH

Development & Manufacturing (CDMO)

Aragen’s Biologics D&M platform provides integrated gene-to-GMP support across cell line development, process and analytical development, and clinical and commercial GMP manufacturing. The platform combines Aragen’s US-based biologics R&D and cell line development capabilities with process development, analytical laboratories and GMP manufacturing infrastructure in India.

We focus on complex biologics development and since Fiscal 2019, we have delivered 54 cell lines to customers. We operate an installed GMP manufacturing capacity of 2.50 KL as of March 31, 2026, supported by process development and analytical laboratories. This was commissioned during the third quarter of Fiscal 2026. 

Aragen’s biologics R&D facility in California has been in operation for over 20 years as of 31 March 2026.

Process Research & Development

Aragen supports upstream process development, downstream process development and analytical method development across biologics research and development programmes.

Bioproduction

Creating R&D cost efficiency with protein and cell reagents.

Developability & Analytics

A broad range of analytical services and capabilities to enable successful biologics characterization and process development in a phase-appropriate manner.

GMP Manufacturing

Meeting your cGMP clinical drug substance needs using our scale-up experience in single-use bioreactors.